217 related articles for article (PubMed ID: 37622124)
1. Neutrophil to Lymphocyte ratio as a predictor for immune-related adverse events in cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis.
Zhang W; Tan Y; Li Y; Liu J
Front Immunol; 2023; 14():1234142. PubMed ID: 37622124
[TBL] [Abstract][Full Text] [Related]
2. Association between pretreatment neutrophil-to-lymphocyte ratio and immune-related adverse events due to immune checkpoint inhibitors in patients with non-small cell lung cancer.
Fujimoto A; Toyokawa G; Koutake Y; Kimura S; Kawamata Y; Fukuishi K; Yamazaki K; Takeo S
Thorac Cancer; 2021 Aug; 12(15):2198-2204. PubMed ID: 34173724
[TBL] [Abstract][Full Text] [Related]
3. Predictive value of NLR and PLR for immune-related adverse events: a systematic review and meta-analysis.
Lu HR; Zhu PF; Deng YY; Chen ZL; Yang L
Clin Transl Oncol; 2024 May; 26(5):1106-1116. PubMed ID: 37682501
[TBL] [Abstract][Full Text] [Related]
4. Peripheral Blood Markers Identify Risk of Immune-Related Toxicity in Advanced Non-Small Cell Lung Cancer Treated with Immune-Checkpoint Inhibitors.
Pavan A; Calvetti L; Dal Maso A; Attili I; Del Bianco P; Pasello G; Guarneri V; Aprile G; Conte P; Bonanno L
Oncologist; 2019 Aug; 24(8):1128-1136. PubMed ID: 31015312
[TBL] [Abstract][Full Text] [Related]
5. Risk factors for adverse events induced by immune checkpoint inhibitors in patients with non-small-cell lung cancer: a systematic review and meta-analysis.
Suazo-Zepeda E; Bokern M; Vinke PC; Hiltermann TJN; de Bock GH; Sidorenkov G
Cancer Immunol Immunother; 2021 Nov; 70(11):3069-3080. PubMed ID: 34195862
[TBL] [Abstract][Full Text] [Related]
6. Neutrophil-to-Lymphocyte Ratio Predicts Development of Immune-Related Adverse Events and Outcomes from Immune Checkpoint Blockade: A Case-Control Study.
Lee PY; Oen KQX; Lim GRS; Hartono JL; Muthiah M; Huang DQ; Teo FSW; Li AY; Mak A; Chandran NS; Tan CL; Yang P; Tai ES; Ng KWP; Vijayan J; Chan YC; Tan LL; Lee MB; Chua HR; Hong WZ; Yap ES; Lim DK; Yuen YS; Chan YH; Aminkeng F; Wong ASC; Huang Y; Tay SH
Cancers (Basel); 2021 Mar; 13(6):. PubMed ID: 33804050
[TBL] [Abstract][Full Text] [Related]
7. Baseline neutrophil-lymphocyte ratio and platelet-lymphocyte ratio appear predictive of immune treatment related toxicity in hepatocellular carcinoma.
Dharmapuri S; Ă–zbek U; Jethra H; Jun T; Marron TU; Saeed A; Huang YH; Muzaffar M; Pinter M; Balcar L; Fulgenzi C; Amara S; Weinmann A; Personeni N; Scheiner B; Pressiani T; Navaid M; Bengsch B; Paul S; Khan U; Bettinger D; Nishida N; Mohamed YI; Vogel A; Gampa A; Korolewicz J; Cammarota A; Kaseb A; Galle PR; Pillai A; Wang YH; Cortellini A; Kudo M; D'Alessio A; Rimassa L; Pinato DJ; Ang C
World J Gastrointest Oncol; 2023 Nov; 15(11):1900-1912. PubMed ID: 38077640
[TBL] [Abstract][Full Text] [Related]
8. Peripheral Blood Markers Associated with Immune-Related Adverse Effects in Patients Who Had Advanced Non-Small Cell Lung Cancer Treated with PD-1 Inhibitors.
Liu W; Liu Y; Ma F; Sun B; Wang Y; Luo J; Liu M; Luo Z
Cancer Manag Res; 2021; 13():765-771. PubMed ID: 33536784
[TBL] [Abstract][Full Text] [Related]
9. Absolute eosinophil count may be an optimal peripheral blood marker to identify the risk of immune-related adverse events in advanced malignant tumors treated with PD-1/PD-L1 inhibitors: a retrospective analysis.
Ma Y; Ma X; Wang J; Wu S; Wang J; Cao B
World J Surg Oncol; 2022 Jul; 20(1):242. PubMed ID: 35897018
[TBL] [Abstract][Full Text] [Related]
10. Continuous monitoring of neutrophils to lymphocytes ratio for estimating the onset, severity, and subsequent prognosis of immune related adverse events.
Matsukane R; Watanabe H; Minami H; Hata K; Suetsugu K; Tsuji T; Masuda S; Okamoto I; Nakagawa T; Ito T; Eto M; Mori M; Nakanishi Y; Egashira N
Sci Rep; 2021 Jan; 11(1):1324. PubMed ID: 33446685
[TBL] [Abstract][Full Text] [Related]
11. Predictive value of neutrophil-lymphocyte ratio and platelet-lymphocyte ratio in non-small cell lung cancer patients treated with immune checkpoint inhibitors: A meta-analysis.
Zhang N; Jiang J; Tang S; Sun G
Int Immunopharmacol; 2020 Aug; 85():106677. PubMed ID: 32531712
[TBL] [Abstract][Full Text] [Related]
12. Predictive biomarkers for immune-related adverse events in cancer patients treated with immune-checkpoint inhibitors.
Wang J; Ma Y; Lin H; Wang J; Cao B
BMC Immunol; 2024 Jan; 25(1):8. PubMed ID: 38267897
[TBL] [Abstract][Full Text] [Related]
13. Blood cell counts can predict adverse events of immune checkpoint inhibitors: A systematic review and meta-analysis.
Zhou J; Du Z; Fu J; Yi X
Front Immunol; 2023; 14():1117447. PubMed ID: 36960068
[TBL] [Abstract][Full Text] [Related]
14. Risk Factors for Immune Checkpoint Inhibitor-Related Pneumonitis in Cancer Patients: A Systemic Review and Meta-Analysis.
Zhou P; Zhao X; Wang G
Respiration; 2022; 101(11):1035-1050. PubMed ID: 36108598
[TBL] [Abstract][Full Text] [Related]
15. Body mass index and immune-related adverse events in patients on immune checkpoint inhibitor therapies: a systematic review and meta-analysis.
Guzman-Prado Y; Ben Shimol J; Samson O
Cancer Immunol Immunother; 2021 Jan; 70(1):89-100. PubMed ID: 32648164
[TBL] [Abstract][Full Text] [Related]
16. Immune-Related Adverse Events by Immune Checkpoint Inhibitors Significantly Predict Durable Efficacy Even in Responders with Advanced Non-Small Cell Lung Cancer.
Akamatsu H; Murakami E; Oyanagi J; Shibaki R; Kaki T; Takase E; Tanaka M; Harutani Y; Yamagata N; Okuda Y; Furuta K; Sugimoto T; Teraoka S; Hayata A; Tokudome N; Ozawa Y; Mori K; Koh Y; Yamamoto N
Oncologist; 2020 Apr; 25(4):e679-e683. PubMed ID: 32297443
[TBL] [Abstract][Full Text] [Related]
17. Safety and Efficacy of the Rechallenge of Immune Checkpoint Inhibitors After Immune-Related Adverse Events in Patients With Cancer: A Systemic Review and Meta-Analysis.
Zhao Q; Zhang J; Xu L; Yang H; Liang N; Zhang L; Zhang F; Zhang X
Front Immunol; 2021; 12():730320. PubMed ID: 34646270
[TBL] [Abstract][Full Text] [Related]
18. Association of blood biomarkers and autoimmunity with immune related adverse events in patients with cancer treated with immune checkpoint inhibitors.
Michailidou D; Khaki AR; Morelli MP; Diamantopoulos L; Singh N; Grivas P
Sci Rep; 2021 Apr; 11(1):9029. PubMed ID: 33907229
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of neutrophil to lymphocyte ratio in gastric cancer patients receiving immune checkpoint inhibitors: a systematic review and meta-analysis.
Zhang S; Qiu C; Yu H; Xu Y; Xu X
Front Oncol; 2023; 13():1070019. PubMed ID: 37143942
[TBL] [Abstract][Full Text] [Related]
20. Neutrophil-to-Lymphocyte Ratio as a Prognostic Biomarker for Patients With Metastatic Renal Cell Carcinoma Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis.
Chen X; Meng F; Jiang R
Front Oncol; 2021; 11():746976. PubMed ID: 34900692
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]